{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:34:45Z","timestamp":1770507285501,"version":"3.49.0"},"reference-count":50,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"abstract":"<jats:p>Although direct oral anticoagulants (DOACs) have become a primary treatment choice for cancer-associated venous thromboembolism (CT), the safety and effectiveness of switching from low-molecular-weight heparin (LMWH) to DOACs in current users remains unclear.<\/jats:p>\n                  <jats:p>To evaluate the safety and effectiveness of switching to DOACs in patients with CT currently receiving LMWH therapy, a territory-wide cohort study using linked claims and registry databases in Taiwan was conducted. Between 2013 and 2021, patients with CT were identified and categorized as switchers to DOACs versus persistent LMWH users. Cox regression and Fine-Gray models with inverse probability of treatment weighting were used to estimate hazard ratios (HRs) for recurrent venous thromboembolism (VTE), major bleeding, and all-cause mortality.<\/jats:p>\n                  <jats:p>A total of 3,885 patients with LMWH-treated CT were included, with 2,103 (54.1%) being women and a mean age of 65.6 years at CT diagnosis, of which 2,373 (59.5%) switched to DOAC therapy. Compared with the persistent use of LMWH, switching to DOACs within 6 months was associated with no significant difference in recurrent VTE (HR: 0.86 [95% CI 0.50-1.49]) and major bleeding (HR: 0.89 [95% CI 0.67-1.18]), with a significantly lower risk of all-cause mortality (HR: 0.67 [95% CI 0.52-0.86]).<\/jats:p>\n                  <jats:p>Switching to DOACs is a safe and effective alternative to continuous LMWH in patients with CT. This recommendation applies regardless of the duration of initial LMWH therapy, overall treatment duration, and across various vulnerable patient groups.<\/jats:p>","DOI":"10.1055\/a-2785-8686","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:58:37Z","timestamp":1770422317000},"source":"Crossref","is-referenced-by-count":0,"title":["Switching Cancer-associated Venous Thromboembolism Treatment from Continuous LMWH to DOACs: An Evaluation"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7617-6323","authenticated-orcid":false,"given":"Wei","family":"Kang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China"},{"name":"Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-6406","authenticated-orcid":false,"given":"Chin-Yao","family":"Shen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Population Health Data Center, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8640-3593","authenticated-orcid":false,"given":"Michael Chun-Yuan","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Population Health Data Center, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-3032","authenticated-orcid":false,"given":"Vincent K. C.","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4696-9434","authenticated-orcid":false,"given":"Shing Fung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore"},{"name":"Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-270X","authenticated-orcid":false,"given":"Wei-Pang","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Center for Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-6096","authenticated-orcid":false,"given":"Caige","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8280-2952","authenticated-orcid":false,"given":"Silvia T. H.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-6786","authenticated-orcid":false,"given":"Yue","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6283-978X","authenticated-orcid":false,"given":"Victor H. F.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"},{"name":"Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":false,"given":"Stephen L.","family":"Chan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-5088","authenticated-orcid":false,"given":"Ka On","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"},{"name":"Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-114X","authenticated-orcid":false,"given":"Aya","family":"El Helali","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-7652","authenticated-orcid":false,"given":"Edward Chia-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Population Health Data Center, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":false,"given":"Esther W.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"},{"name":"The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, China"},{"name":"Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"A A Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"14","key":"ref2","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/rth2.12274","article-title":"Patient Experience of Living With Cancer-Associated Thrombosis in Canada (PELICANADA)","volume":"4","author":"S Noble","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"S 01","key":"ref4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2018-99-113581","article-title":"Economic burden of venous thromboembolism in cancer patients\u2014a comparative analysis between matched patients with cancer with and without a diagnosis of venous thromboembolism","volume":"132","author":"S Shah","year":"2018","journal-title":"Blood"},{"issue":"08","key":"ref5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/phar.2298","article-title":"Potential role of direct oral anticoagulants in the management of heparin-induced thrombocytopenia","volume":"39","author":"A Barlow","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref7","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"R D McBane II","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"17","key":"ref9","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"e2036304","DOI":"10.1001\/jamanetworkopen.2020.36304","article-title":"Comparison between non-vitamin K antagonist oral anticoagulants and low-molecular-weight heparin in Asian individuals with cancer-associated venous thromboembolism","volume":"4","author":"D Y Chen","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"W Ageno","year":"2016","journal-title":"Lancet Haematol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12959-020-00221-2","article-title":"Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre","volume":"18","author":"A Faqah","year":"2020","journal-title":"Thromb J"},{"issue":"17","key":"ref13","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/bloodadvances.2020002242","article-title":"Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism","volume":"4","author":"O S Costa","year":"2020","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"106567","DOI":"10.1016\/j.vph.2019.106567","article-title":"Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study","volume":"120","author":"K Stepien","year":"2019","journal-title":"Vascul Pharmacol"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-0040-1714739","article-title":"Anticoagulation treatment in cancer-associated venous thromboembolism: assessment of patient preferences using a discrete choice experiment (COSIMO study)","volume":"121","author":"N Picker","year":"2021","journal-title":"Thromb Haemost"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2019.05.012","article-title":"Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States","volume":"180","author":"A Li","year":"2019","journal-title":"Thromb Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.thromres.2020.08.014","article-title":"Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil","volume":"196","author":"D G Lopes","year":"2020","journal-title":"Thromb Res"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"2375269","DOI":"10.1080\/20523211.2024.2375269","article-title":"Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis","volume":"17","author":"W Kang","year":"2024","journal-title":"J Pharm Policy Pract"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"J F Timp","year":"2013","journal-title":"Blood"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1038\/s41467-024-50037-1","article-title":"Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis","volume":"15","author":"W Kang","year":"2024","journal-title":"Nat Commun"},{"issue":"15","key":"ref21","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.3390\/cancers13153861","article-title":"Association between androgen deprivation therapy and risk of dementia in men with prostate cancer","volume":"13","author":"J M Liu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"n1925","DOI":"10.1136\/bmj.n1925","article-title":"Use of antipsychotic drugs and cholinesterase inhibitors and risk of falls and fractures: self-controlled case series","volume":"374","author":"G H Wang","year":"2021","journal-title":"BMJ"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.7326\/M21-3498","article-title":"Diabetes-related complications and mortality in patients with atrial fibrillation receiving different oral anticoagulants: a nationwide analysis","volume":"175","author":"H K Huang","year":"2022","journal-title":"Ann Intern Med"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40259-022-00528-8","article-title":"Comparative treatment persistence with bone-targeting agents among Asian patients with bone metastases from solid tumors: a multinational retrospective cohort study","volume":"36","author":"C Y Shen","year":"2022","journal-title":"BioDrugs"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"A A Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/S2352-3026(15)00027-7","article-title":"Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study","volume":"2","author":"K Bouillon","year":"2015","journal-title":"Lancet Haematol"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11239-023-02791-0","article-title":"Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies","volume":"55","author":"R Robinson","year":"2023","journal-title":"J Thromb Thrombolysis"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"M E Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.14309\/ajg.0000000000000678","article-title":"Association between nonvitamin K antagonist oral anticoagulants or warfarin and liver injury: a cohort study","volume":"115","author":"J Zhao","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"35","key":"ref31","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis","volume":"30","author":"S Seng","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"e0189410","DOI":"10.1371\/journal.pone.0189410","article-title":"Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer","volume":"12","author":"E S Kim","year":"2017","journal-title":"PLoS One"},{"issue":"05","key":"ref34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"A Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"07","key":"ref36","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"D Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"09","key":"ref37","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1055\/a-1777-4006","article-title":"Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors","volume":"122","author":"R Lecumberri","year":"2022","journal-title":"Thromb Haemost"},{"issue":"8961","key":"ref38","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(95)92535-X","article-title":"Accuracy of clinical assessment of deep-vein thrombosis","volume":"345","author":"P S Wells","year":"1995","journal-title":"Lancet"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"B Planquette","year":"2022","journal-title":"Chest"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"E von Elm","year":"2014","journal-title":"Int J Surg"},{"issue":"32","key":"ref41","doi-asserted-by":"crossref","first-page":"e26883","DOI":"10.1097\/MD.0000000000026883","article-title":"Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation: a PRISMA-compliant article","volume":"100","author":"S M Kim","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"05","key":"ref42","first-page":"789","article-title":"Stroke prevention in atrial fibrillation: an Asian perspective","volume":"111","author":"C E Chiang","year":"2014","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/ajh.25604","article-title":"Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism","volume":"94","author":"W E Wysokinski","year":"2019","journal-title":"Am J Hematol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.thromres.2021.03.026","article-title":"Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism","volume":"202","author":"A Douros","year":"2021","journal-title":"Thromb Res"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.3802\/jgo.2020.31.e10","article-title":"Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers","volume":"31","author":"J H Lee","year":"2020","journal-title":"J Gynecol Oncol"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jth.13563","article-title":"Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice","volume":"15","author":"S J van der Wall","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/jth.15153","article-title":"Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs","volume":"19","author":"J K Schaefer","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref48","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/jcm9051398","article-title":"Non-vitamin K antagonist oral anticoagulants and the gastrointestinal bleeding risk in real-world studies","volume":"9","author":"L Anghel","year":"2020","journal-title":"J Clin Med"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.7326\/M21-1474","article-title":"Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: a nationwide propensity score-weighted study","volume":"174","author":"A B Ingason","year":"2021","journal-title":"Ann Intern Med"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study","volume":"175","author":"W CY Lau","year":"2022","journal-title":"Ann Intern Med"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11239-023-02926-3","article-title":"Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: a systematic review and meta-analysis of observational studies","volume":"57","author":"D Fredman","year":"2024","journal-title":"J Thromb Thrombolysis"},{"issue":"15","key":"ref52","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1182\/bloodadvances.2019000572","article-title":"Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world","volume":"3","author":"M R Aryal","year":"2019","journal-title":"Blood Adv"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2785-8686.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:58:44Z","timestamp":1770422324000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2785-8686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1055\/a-2785-8686","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}